FOR IMMEDIATE RELEASE
March 27, 2017
CANNABCO PHARMACEUTICAL CORP. ENTERS FINAL STAGES OF FEDERAL LICENSING FOR PRODUCTION OF MEDICAL MARIJUANA
CANNABCO ENTERS FINAL REVIEW STAGE WITH HEALTH CANADA
TORONTO , March 27, 2017 /CNW/ - Cannabco Pharmaceutical Corp. (“Cannabco” or the “Company”) is pleased to announce that the company has entered final stages of federal licensing with Health Canada in order to become one of Canada’s next Licensed Producers of Medical Marijuana. The company’s two state of the art production facilities, both located in the Greater Toronto Area, employ the most advanced cultivation technologies to date and have a combined production capability of over 15,000 Kilograms of Dried Cannabis annually. Notification of final Review was received from Health Canada early March of 2017.
“It’s been a long road requiring a tremendous amount of work, dedication, and patience that has ultimately paid off.” said President and CEO Mark Pellicane, “This is a tremendous step forward for Cannabco, and we look forward to the prospect of receiving our ACMPR license in due course with Health Canada and commencing production.”
Cannabco's business plan involves the on-going production and supply of pharmaceutical grade Cannabis to both the fast growing medical market and upcoming recreational markets across Canada. Cannabco will cultivate and harvest the crops using controlled state of the art hydroponic facilities and utilize some of the industry’s most advanced technologies to cultivate a superior quality of product at an unprecedented low cost of production. Licensing and distribution is in accordance with Health Canada’s ‘Access to Cannabis for Medical Purposes Regulations’ (ACMPR) to licensed markets including pharmaceutical companies, medical users, global export, and purposed recreational markets.
“It’s an exciting time.” said Mark Novak, Director of Operations, “Cannabco is now primed to move forward for inspection and cultivation licensing by Health Canada.”
Upon completion and licensing of its facilities, Cannabco intends to cultivate medical strains targeting specific illnesses, as well as popular strains geared towards recreational markets once the distribution framework has been finalized by the Canadian Government.
Cannabco Pharmaceutical Corporation (‘Cannabco’) was established with the intent of becoming a licensed Cannabis producer under Health Canada’s ACMPR program. The company is dedicated to establishing itself as a leader in top quality affordable pharmaceutical grade Marijuana supply and cutting edge research contributing to the growing needs of Canadians. Cannabco employs the most advanced cultivation technologies with a focus on increased yields at reduced production costs while maintaining high quality Pharmaceutical grade output for its clients.
Phillip Chen, Business Development
(905) 771-8576 x 231
Source: Cannabco Pharmaceutical Corp.